In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sweden's Hemp-Derived CBD Market Under Threat Following Supreme Court Ruling

Executive Summary

CBD from industrial hemp that contains any trace of THC, however small, is a controlled drug, Sweden's Supreme Court has ruled. The country has moved to close a legal loophole that was being taken advantage of by retailers to avoid prosecution for selling CBD oils as supplements.

You may also be interested in...



Germany And Sweden Leading The EU In CBD Enforcement Action

Sweden and Germany are cracking down on unauthorized CBD food products and warning their neighbors of the health risks posed to consumers, an analysis by HBW Insight reveals. A large proportion of these CBD products are being sold as food supplements and many originate from the Netherlands. 

Confusion Reigns In UK CBD Market As Regulatory Vacuum Allowed To Continue

Major retailers LloydsPharmacy and Holland & Barrett remain unfazed by the regulatory chaos surrounding cannabidiol (CBD) in the UK, while pharmacy groups become increasingly concerned that their members may be selling controlled substances due to the possible presence of tetrahydrocannabinol (THC).

Medical Marijuana Inc. Claims First CBD Supplement Approval In EU

Bulgaria has granted US-based Medical Marijuana Inc. the right to sell CBD as a supplement in a first for an EU country. The move, which will see CBD regulated as a traditional food, puts Bulgaria directly at odds with the European Commission, which recently classified the cannabis plant extract as a novel food.

Related Content

Topics

UsernamePublicRestriction

Register

MT065510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel